Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone

American Journal of Pathology

Volumn 168, Issue 2, 2006, Pages 551-561

  Natasha, Tajneen ^a   Kuhn, Misty ^a,c   Kelly, Owen ^a   Rittling, Susan R ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b FORSYTH INSTITUTE   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; RNA; SIALOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BREAST CANCER; BREAST EPITHELIUM; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENOTYPE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR GROWTH;

EID: 33144458447     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050480     Document Type: Article

References (45)

1. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98:1544-1549
2. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206
3. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664
4. Yoneda T, Hiraga T: Crosstalk between cancer cells and bone micro-environment in bone metastasis. Biochem Biophys Res Commun 2005, 328:679-687
5. Chen Y, Rittling SR: Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing. Clin Exp Metastasis 2003, 20:111-120
6. Rittling SR, Denhardt DT: Osteopontin (OPN) function in pathology: lessons from OPN-deficient mice. Exp Nephrol 1999, 7:103-113
7. Yamate T, Mocharla H, Taguchi Y, Igietseme JU, Manolagas SC, Abe E: Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. Endocrinology 1997, 138:3047-3055
8. Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E, Gowen M: Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner Res 1995, 10:1666-1680
9. Yoshitake H, Rittling SR, Denhardt DT, Noda M: Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption [published erratum appears in Proc Natl Acad Sci USA 1999 Sep 14; 96(19): 10944]. Proc Natl Acad Sci USA 1999, 96:8156-8160
10. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Noda M: Resistance to unloading-induced three-dimensional bone loss in osteopontin-deficient mice. J Bone Miner Res 2002, 17:661-667
11. Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M: Parathyroid hormone-induced bone resorption does not occur in the absence of Osteopontin. J Biol Chem 2001, 276:13065-13071
12. Aitken CJ, Hodge JM, Nicholson GC: Adenoviral down-regulation of Osteopontin inhibits human osteoclast differentiation in vitro. J Cell Biochem 2004, 93:896-903
13. Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J: Colocalization of intracellular Osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 2002, 17:1486-1497
14. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, Hruska KA: Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003, 14:173-189
15. Rittling SR, Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881
16. Tuck AB, Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001, 6:419-429
17. Wu Y, Denhardt DT, Rittling SR: Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000, 83:156-163
18. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994, 54:832-837
19. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549
20. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT: Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998, 13:1101-1111
21. Arguello F, Baggs RB, Frantz CN: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988, 48:6876-6881
22. Feng F, Rittling SR: Mammary tumor development in MMTV-c-myc/MMTV-v-Ha- ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat 2000, 63:71-79
23. Rittling SR, Chen Y, Feng F, Wu Y: Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002, 277:9175-9182
24. Anway MD, Wright WW, Zirkin BR, Korah N, Wort JS, Hermo L: Expression and localization of cathepsin k in adult rat Sertoli cells. Biol Reprod 2004, 70:562-569
25. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176
26. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50
27. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M: Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001, 16:652-659
28. Vermeirsch H, Nuydens RM, Salmon PL, Meert TF: Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity. Pharmacol Biochem Behav 2004, 79:243-251
29. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS: Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001, 280:460-465
30. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B, Cheifetz S: Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000, 18:253-260
31. Sharp JA, Waitham M, Williams ED, Henderson MA, Thompson EW: Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis 2004, 21:19-29
32. Crawford HC, Matrisian LM, Liaw L: Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998, 58:5206-5215
33. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864
34. Weiss JM, Renkl AC, Maier CS, Kimmig M, Liaw L, Ahrens T, Kon S, Maeda M, Hotta H, Uede T, Simon JC: Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001, 194:1219-1229
35. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, Segawa T, Maeda M, Hamuro J, Nakayama T, Taniguchi M, Yagita H, Van Kaer L, Onoe K, Denhardt D, Rittling S, Uede T: Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004, 21:539-550
36. Bourassa B, Monaghan S, Rittling SR: Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol 2004, 227:1-11
37. Iguchi H, Onuma E, Sato K, Sato K, Ogata E: Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen, Int J Cancer 2001, 94:24-27
38. van Halteren HK, Bongaerts GP, Wagener DJ: Cancer cachexia: what is known about its etiology and what should be the current treatment approach? Anticancer Res 2003, 23:5111-5115
39. Ishipma M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M: Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001, 193:399-404
40. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CA, Sodek J: Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 2004, 198:155-167
41. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J: Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000, 184:118-130
42. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL: Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105:433-440
43. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, Ross FP, Teitelbaum SL: The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003, 198:771-781
44. Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC: Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 2004, 279:54841-54848
45. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowiand N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN: Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003, 100:14205-14210